DA Davidson Upgrades USANA Health Sciences (NYSE:USNA) to Hold

USANA Health Sciences (NYSE:USNA) was upgraded by analysts at DA Davidson to a “hold” rating in a research note issued to investors on Friday,Zacks.com reports.

Separately, StockNews.com raised USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday.

USANA Health Sciences Price Performance

USNA stock opened at $33.38 on Friday. The company has a 50 day simple moving average of $37.91 and a 200 day simple moving average of $40.37. The stock has a market cap of $636.22 million, a price-to-earnings ratio of 11.80, a P/E/G ratio of 1.25 and a beta of 0.89. USANA Health Sciences has a 1 year low of $33.28 and a 1 year high of $54.81.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.49 by $0.07. The company had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same period last year, the business posted $0.59 EPS. On average, equities research analysts anticipate that USANA Health Sciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by company insiders.

Institutional Trading of USANA Health Sciences

Several institutional investors have recently modified their holdings of the company. American Century Companies Inc. grew its stake in shares of USANA Health Sciences by 12.3% during the second quarter. American Century Companies Inc. now owns 159,782 shares of the company’s stock valued at $7,229,000 after purchasing an additional 17,460 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of USANA Health Sciences by 13.5% in the third quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock valued at $4,702,000 after purchasing an additional 14,756 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in USANA Health Sciences by 14,068.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock valued at $1,472,000 after purchasing an additional 38,547 shares during the last quarter. Pzena Investment Management LLC raised its stake in USANA Health Sciences by 24.4% in the 2nd quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock valued at $44,183,000 after acquiring an additional 191,289 shares during the period. Finally, Deerfield Management Company L.P. Series C grew its holdings in USANA Health Sciences by 297.0% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 29,742 shares of the company’s stock valued at $1,346,000 after buying an additional 22,251 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.